Pittsburgh-based UPMC Enterprises has made an equity investment in RxAnte, a predictive analytics and clinical intervention solution provider focused on inappropriate medication use. The transaction closed Sept. 30.
RxAnte uses predictive analytics to improve prescribing practices and appropriate use of prescription medications. With UPMC Enterprises' investment, the company plans to continue with product development, collaborating with clinical experts at UPMC.
"Improving medication use is increasingly recognized as one of the biggest but most challenging opportunities to improve patient outcomes while reducing healthcare costs," Tal Heppenstall, president of UPMC Enterprises, said in a statement. "With its deep understanding of the predictive power of data and suite of tools for using data to change behavior, RxAnte is key to our strategy of developing and deploying smart technology to address the toughest challenges in healthcare."
UPMC Health Plan has been a customer of RxAnte for the past three years. RxAnte currently manages medication use for close to 7 million people.
More articles on health IT:
6 things to know about Apple's foray into healthcare
Balancing technology with healthcare's human narrative: A Q&A with Dr. Abha Agrawal
Wolters Kluwer acquires Emmi Solutions for $170M